Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients.

Publication date: Dec 31, 2024

The durability of the immunogenicity elicited by three doses of mRNA-based BNT162b2 and whole-virus inactivated CoronaVac in patients with neuromuscular diseases, particularly those on immunosuppressive drugs and variants of concern, has not been well-established. Our goal was to evaluate medium-term humoral immunogenicity outcomes after 3 doses of these vaccines. Peripheral blood samples were collected from participants 14-49 days and 155-210 days after administration of the third vaccine dose to assess humoral immune responses through serological assays. The immunogenicity outcomes of each patient were compared to those of three age-matched healthy control participants, ensuring a balanced comparison. Both patients that received 3 doses of BNT162b2 and 10 (90. 9%) patients that received CoronaVac seroconverted against wild-type-SARS-CoV-2 virus, showing comparable antibody responses to healthy participants. After 6 months, one patient in BNT162b2 and all four patients in CoronaVac groups maintained seropositivity. The JN-1 specific binding antibody response was lower compared to wild-type virus. The use of corticosteroids did not affect seroconversion rate against wild-type virus or JN. 1 variant. BNT162b2 and CoronaVac were immunogenic for neuromuscular diseases patients, maintaining durability after 6 months even for those on corticosteroids. Our data support a rapid immunization series utilizing mRNA-based and whole-virus inactivated vaccines for future pandemic.

Concepts Keywords
49days Adult
Bnt162b2 Aged
Healthy Antibodies, Viral
Immunosuppressive Antibodies, Viral
Inactivated BNT162 Vaccine
BNT162 Vaccine
BNT162b2
CoronaVac
COVID-19
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Hong Kong
Humans
immunogenicity
Immunogenicity, Vaccine
Male
Middle Aged
Neuromuscular Diseases
neuromuscular diseases
SARS-CoV-2
SARS-CoV-2 inactivated vaccines
Seroconversion
sinovac COVID-19 vaccine
Vaccines, Inactivated
Vaccines, Inactivated

Semantics

Type Source Name
disease MESH neuromuscular disease
disease IDO blood
disease MESH seroconversion
disease MESH COVID-19

Original Article

(Visited 1 times, 1 visits today)